Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0UJ0K
|
||||
| Former ID |
DIB021037
|
||||
| Drug Name |
tetraethylammonium
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [539487] | ||
| Formula |
C8H20N+
|
||||
| InChI |
InChI=1S/C8H20N/c1-5-9(6-2,7-3)8-4/h5-8H2,1-4H3/q+1
|
||||
| InChIKey |
CBXCPBUEXACCNR-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9715, 560558, 561143, 823293, 823821, 1434686, 5617425, 6903206, 7887259, 7889355, 8002309, 8153330, 11111868, 15297244, 24263038, 26697167, 29224465, 37356638, 49868992, 50111261, 53790517, 57322763, 76453784, 90340838, 103168691, 104037965, 104309173, 106812165, 124750303, 124881591, 125659879, 126677961, 126678584, 127299839, 127299840, 127299841, 127299842, 127299843, 127299844, 127299845, 127299846, 127299847, 127299848, 127299849, 127299850, 127299851, 127299852, 127299853, 127602502, 127838406
|
||||
| Target and Pathway | |||||
| Target(s) | Potassium voltage-gated channel subfamily KQT member 2 | Target Info | Blocker (channel blocker) | [525854] | |
| TRPV2 | Target Info | Blocker (channel blocker) | [528975] | ||
| Kv1.6 | Target Info | Blocker (channel blocker) | [532260] | ||
| KNa1.1 | Target Info | Blocker (channel blocker) | [527608] | ||
| AQP1 | Target Info | Inhibitor | [543916] | ||
| KCa2.2 | Target Info | Blocker (channel blocker) | [530822] | ||
| Kir2.3 | Target Info | Blocker (channel blocker) | [533867] | ||
| Kv1.8 | Target Info | Blocker (channel blocker) | [525781] | ||
| KCa2.3 | Target Info | Blocker (channel blocker) | [530822] | ||
| Kv1.2 | Target Info | Blocker (channel blocker) | [533612] | ||
| Kv3.3 | Target Info | Blocker (channel blocker) | [526804] | ||
| Kv2.2 | Target Info | Blocker (channel blocker) | [534639] | ||
| Potassium channel KCNA1 Kv1.1 | Target Info | Blocker (channel blocker) | [533612] | ||
| Potassium voltage-gated channel subfamily A member 3 | Target Info | Blocker (channel blocker) | [533612] | ||
| KCa2.1 | Target Info | Blocker (channel blocker) | [530822] | ||
| KNa1.2 | Target Info | Blocker (channel blocker) | [528200] | ||
| Kv7.5 | Target Info | Blocker (channel blocker) | [525770] | ||
| Potassium voltage-gated channel subfamily KQT member 4 | Target Info | Blocker (channel blocker) | [529688] | ||
| Kv3.1 | Target Info | Blocker (channel blocker) | [533612] | ||
| Potassium voltage-gated channel subfamily KQT member 3 | Target Info | Blocker (channel blocker) | [525715] | ||
| Maxi K potassium channel | Target Info | Inhibitor | [543803] | ||
| Kv4.1 | Target Info | Blocker (channel blocker) | [526433] | ||
| KCa5.1 | Target Info | Blocker (channel blocker) | [530535] | ||
| Potassium voltage-gated channel subfamily B member 1 | Target Info | Blocker (channel blocker) | [528030] | ||
| Potassium voltage-gated channel subfamily A member 5 | Target Info | Blocker (channel blocker) | [533612] | ||
| Kv3.4 | Target Info | Blocker (channel blocker) | [526800] | ||
| Kv3.2 | Target Info | Blocker (channel blocker) | [526249] | ||
| Kv1.7 | Target Info | Blocker (channel blocker) | [526293] | ||
| PANTHER Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | ||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Voltage gated Potassium channels | ||||
| Interaction between L1 and AnkyrinsR-HSA-1296072:Voltage gated Potassium channelsR-HSA-1296072:Voltage gated Potassium channelsR-HSA-1296072:Voltage gated Potassium channelsR-HSA-1296072:Voltage gated Potassium channels | |||||
| Interaction between L1 and AnkyrinsR-HSA-418457:cGMP effectsR-HSA-1296072:Voltage gated Potassium channels | |||||
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretionR-HSA-1296072:Voltage gated Potassium channels | |||||
| WikiPathways | Potassium Channels | ||||
| L1CAM interactionsWP2669:Potassium ChannelsWP2669:Potassium Channels | |||||
| BDNF signaling pathwayWP2669:Potassium ChannelsWP2669:Potassium Channels | |||||
| L1CAM interactionsWP2669:Potassium Channels | |||||
| Platelet homeostasisWP536:Calcium Regulation in the Cardiac Cell | |||||
| Potassium ChannelsWP2669:Potassium Channels | |||||
| References | |||||
| Ref 525715 | Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol. 2000 Feb;129(3):413-5. | ||||
| Ref 525770 | KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem. 2000 Aug 4;275(31):24089-95. | ||||
| Ref 525781 | KCNA10: a novel ion channel functionally related to both voltage-gated potassium and CNG cation channels. Am J Physiol Renal Physiol. 2000 Jun;278(6):F1013-21. | ||||
| Ref 525854 | Mol Pharmacol. 2000 Sep;58(3):591-600.Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. | ||||
| Ref 526249 | Gating, modulation and subunit composition of voltage-gated K(+) channels in dendritic inhibitory interneurones of rat hippocampus. J Physiol. 2002 Jan 15;538(Pt 2):405-19. | ||||
| Ref 526293 | Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). Eur J Hum Genet. 2002 Jan;10(1):36-43. | ||||
| Ref 526433 | Endogenous Kv channels in human embryonic kidney (HEK-293) cells. Mol Cell Biochem. 2002 Sep;238(1-2):69-79. | ||||
| Ref 526800 | Characterization of a Shaw-related potassium channel family in rat brain. EMBO J. 1992 Jul;11(7):2473-86. | ||||
| Ref 526804 | Cloning of ShIII (Shaw-like) cDNAs encoding a novel high-voltage-activating, TEA-sensitive, type-A K+ channel. Proc Biol Sci. 1992 Apr 22;248(1321):9-18. | ||||
| Ref 527608 | For K+ channels, Na+ is the new Ca2+. Trends Neurosci. 2005 Aug;28(8):422-8. | ||||
| Ref 528030 | Modulation of Kv2.1 channel gating and TEA sensitivity by distinct domains of SNAP-25. Biochem J. 2006 Jun 1;396(2):363-9. | ||||
| Ref 528200 | Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68. | ||||
| Ref 528975 | Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxydiphenyl borate. Mol Pharmacol. 2007 Nov;72(5):1258-68. Epub 2007 Aug 2. | ||||
| Ref 529688 | Homomeric and heteromeric assembly of KCNQ (Kv7) K+ channels assayed by total internal reflection fluorescence/fluorescence resonance energy transfer and patch clamp analysis. J Biol Chem. 2008 Nov 7;283(45):30668-76. | ||||
| Ref 530535 | Block of mouse Slo1 and Slo3 K+ channels by CTX, IbTX, TEA, 4-AP and quinidine. Channels (Austin). 2010 Jan-Feb;4(1):22-41. Epub 2010 Jan 2. | ||||
| Ref 530822 | Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. | ||||
| Ref 532260 | Cloning and expression of a human voltage-gated potassium channel. A novel member of the RCK potassium channel family. EMBO J. 1990 Jun;9(6):1749-56. | ||||
| Ref 533612 | Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34. | ||||
| Ref 533867 | Cloning and expression of a novel human brain inward rectifier potassium channel. J Biol Chem. 1994 Aug 12;269(32):20468-74. | ||||
| Ref 534639 | Molecular identification of a component of delayed rectifier current in gastrointestinal smooth muscles. Am J Physiol. 1998 May;274(5 Pt 1):G901-11. | ||||
| Ref 543803 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 380). | ||||
| Ref 543916 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 688). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.